Literature DB >> 16475693

Longitudinal evaluation of tumor metastasis by an FDG-microPet/microCT dual-imaging modality in a lung carcinoma-bearing mouse model.

Chih-Hsien Chang1, Meei-Lin Jan, Kuo-Hsien Fan, Hsin-Ell Wang, Tung-Hu Tsai, Chieh-Fu Chen, Ying-Kai Fu, Te-Wei Lee.   

Abstract

BACKGROUND: Histological methods are used to define the growth and response to various treatments of lung carcinoma in mice. The aim of the study was to evaluate a quantitative and 3D-tomographic microPET/microCT dual-image modality using 18F-fluorodeoxyglucose (FDG) to monitor the tumor progression in an experimental metastasis mouse model.
MATERIALS AND METHODS: Six normal mice were subjected to FDG-microPET/microCT image scan to present the normal thorax morphology. Twenty-one 8-week-old male C57BL/6 mice were inoculated with 1 x 10(6) Lewis lung carcinoma cells (LLC1) through the lateral tail vein. FDG-microPET/microCT scans were performed on days 0, 5, 9, 13 and 18 (n=6) to monitor the growth of the tumor. MicroPET and microCT images were further used to monitor the metastasis of the lung carcinoma to the liver. Fifteen mice were sacrificed for biodistribution on days 0, 5, 9, 13 and 18 after the inoculation of lung carcinoma cells.
RESULTS: The FDG-microPET/microCT dual-image modality showed that the growth of the tumor could be monitored longitudinally. The standard uptake value (SUV) of FDG increased from 0.63 +/- 0.05 on day 0 to 1.03 +/- 0.15 on day 18, reflecting the growth of the tumor in mice. The tumors located in the lung and liver could be clearly visualized by the fusion of microPET and microCT images, and further confirmed by whole-body autoradiography or H&E stain.
CONCLUSION: By FDG-microPET, the increase in SUV provided an alternative for assessing the growth of a tumor in vivo. Our results suggest that the growth progression of lung carcinoma can be identified using the FDG-microPET/microCT dual-image modality longitudinally in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16475693

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Optimized murine lung preparation for detailed structural evaluation via micro-computed tomography.

Authors:  Dragos M Vasilescu; Lars Knudsen; Matthias Ochs; Ewald R Weibel; Eric A Hoffman
Journal:  J Appl Physiol (1985)       Date:  2011-08-04

2.  Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.

Authors:  Sharon K Michelhaugh; Otto Muzik; Anthony R Guastella; Neil V Klinger; Lisa A Polin; Hancheng Cai; Yangchun Xin; Thomas J Mangner; Shaohui Zhang; Csaba Juhász; Sandeep Mittal
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

3.  Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.

Authors:  Chia-Che Tsai; Chih-Hsien Chang; Liang-Cheng Chen; Ya-Jen Chang; Keng-Li Lan; Yu-Hsien Wu; Chin-Wei Hsu; I-Hsiang Liu; Chung-Li Ho; Wan-Chi Lee; Hsiao-Chiang Ni; Tsui-Jung Chang; Gann Ting; Te-Wei Lee
Journal:  Int J Nanomedicine       Date:  2011-10-26

4.  Lung tumour growth kinetics in SPC-c-Raf-1-BB transgenic mice assessed by longitudinal in-vivo micro-CT quantification.

Authors:  Thomas Rodt; Christian von Falck; Sabine Dettmer; Katja Hueper; Roman Halter; Ludwig Hoy; Matthias Luepke; Juergen Borlak; Frank Wacker
Journal:  J Exp Clin Cancer Res       Date:  2012-02-20

5.  Tumor burden talks in cancer treatment with PEGylated liposomal drugs.

Authors:  Yi-Yu Lin; Hao-Wen Kao; Jia-Je Li; Jeng-Jong Hwang; Yun-Long Tseng; Wuu-Jyh Lin; Ming-Hsien Lin; Gann Ting; Hsin-Ell Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

6.  Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy.

Authors:  Maider Zabala; Pilar Alzuguren; Carolina Benavides; Julien Crettaz; Gloria Gonzalez-Aseguinolaza; Carlos Ortiz de Solorzano; Manuela Gonzalez-Aparicio; Maria Gabriela Kramer; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Mol Cancer       Date:  2009-01-07       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.